Empower: tDCS for Major Depressive Disorder at Home
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05202119 |
Recruitment Status :
Completed
First Posted : January 21, 2022
Last Update Posted : November 28, 2023
|
Sponsor:
Flow Neuroscience AB
Collaborators:
University of Texas
University of East London
Information provided by (Responsible Party):
Flow Neuroscience AB
Tracking Information | |||||||
---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | January 9, 2022 | ||||||
First Posted Date ICMJE | January 21, 2022 | ||||||
Last Update Posted Date | November 28, 2023 | ||||||
Actual Study Start Date ICMJE | May 1, 2022 | ||||||
Actual Primary Completion Date | June 6, 2023 (Final data collection date for primary outcome measure) | ||||||
Current Primary Outcome Measures ICMJE |
HDRS-17 [ Time Frame: 10 weeks ] Mean score change based on HDRS-17 scores of the two arms at 10 weeks compared to baseline.
|
||||||
Original Primary Outcome Measures ICMJE | Same as current | ||||||
Change History | |||||||
Current Secondary Outcome Measures ICMJE | Not Provided | ||||||
Original Secondary Outcome Measures ICMJE | Not Provided | ||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||
Descriptive Information | |||||||
Brief Title ICMJE | Empower: tDCS for Major Depressive Disorder at Home | ||||||
Official Title ICMJE | Empower: Transcranial Direct Current Stimulation in Major Depressive Disorder: a Double-blind, Placebo-controlled, Randomized, Superiority Trial | ||||||
Brief Summary | A two-center trial to investigate whether or not active stimulation with the Flow FL-100 tDCS device is superior to sham stimulation for the treatment of major depressive disorder when used at home. Participants perform up to 36 tDCS sessions by themselves without supervision during a blinded 10-week phase, and then 30 more sessions during an unblinded open-label phase. |
||||||
Detailed Description | Not Provided | ||||||
Study Type ICMJE | Interventional | ||||||
Study Phase ICMJE | Not Applicable | ||||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Care Provider, Investigator) Masking Description: Participants and investigators are unaware of what stimulation (active or sham) the device delivers. Primary Purpose: Treatment
|
||||||
Condition ICMJE | Major Depressive Disorder | ||||||
Intervention ICMJE |
|
||||||
Study Arms ICMJE |
|
||||||
Publications * | Not Provided | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||
Recruitment Information | |||||||
Recruitment Status ICMJE | Completed | ||||||
Actual Enrollment ICMJE |
174 | ||||||
Original Estimated Enrollment ICMJE |
270 | ||||||
Actual Study Completion Date ICMJE | August 31, 2023 | ||||||
Actual Primary Completion Date | June 6, 2023 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
are taking a stable antidepressant regimen with a stable medication source and agree to continue the same regimen throughout study participation
Exclusion Criteria:
|
||||||
Sex/Gender ICMJE |
|
||||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||||
Accepts Healthy Volunteers ICMJE | No | ||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||
Listed Location Countries ICMJE | United Kingdom, United States | ||||||
Removed Location Countries | |||||||
Administrative Information | |||||||
NCT Number ICMJE | NCT05202119 | ||||||
Other Study ID Numbers ICMJE | FL001 | ||||||
Has Data Monitoring Committee | Not Provided | ||||||
U.S. FDA-regulated Product |
|
||||||
IPD Sharing Statement ICMJE | Not Provided | ||||||
Current Responsible Party | Flow Neuroscience AB | ||||||
Original Responsible Party | Same as current | ||||||
Current Study Sponsor ICMJE | Flow Neuroscience AB | ||||||
Original Study Sponsor ICMJE | Same as current | ||||||
Collaborators ICMJE |
|
||||||
Investigators ICMJE | Not Provided | ||||||
PRS Account | Flow Neuroscience AB | ||||||
Verification Date | November 2023 | ||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |